Skip to main content

Table 1 Clinical characteristics and genomic profiling of PC GC and non-PC GC patients (N = 556)

From: FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma

 

No. of patients

PC

n = 64 (%)

Non-PC

n = 492 (%)

Pb

Age (years)

556

  

0.004

 < 60

270

42 (65.6%)

228 (46.3%)

 

 ≥ 60

286

22 (34.4%)

264 (53.7%)

 

Gender

556

  

0.208

 Male

369

38 (59.4%)

331 (67.3%)

 

 Female

187

26 (40.6%)

161 (32.7%)

 

MSI status

545

  

0.085

 MSS

516

64 (100%)

452 (91.8%)

 

 MSI-H

29

0 (0%)

29 (5.9%)

 

TMBa

556

  

0.001

 TMB-L

411

58 (90.6%)

353 (71.7%)

 

 TMB-H

145

6 (9.4%)

139 (28.3%)

 

Gene SNVs and INDELs

 TP53

349

30 (46.9%)

319 (64.8%)

0.005

 CDH1

80

18 (28.1%)

62 (12.6%)

0.001

 ARID1A

98

9 (14%)

89 (18.1%)

0.426

 ERBB2

29

6 (9.4%)

23 (4.7%)

0.196

 CDKN2A

17

4 (6.3%)

13 (2.6%)

0.234

 RHOA

32

4 (6.3%)

28 (5.7%)

1.000

 SMAD4

33

2 (3.1%)

31 (6.3%)

0.465

Gene CNVs

 FGFR2

33

8 (12.5%)

25 (5.1%)

0.037

 CCNE1

63

2 (3.1%)

61 (12.4%)

0.028

 ERBB2

42

1 (1.6%)

41 (8.3%)

0.094

 VEGFA

28

1 (1.6%)

27 (5.5%)

0.295

Gene rearrangements

 FGFR2

8

2 (3.1%)

6 (1.2%)

0.518

  1. CNV copy number variations, INDEL short and long insertion/deletion, MSI microsatellite instability, MSI-H microsatellite instability-high, MSS microsatellite stable, PC poorly cohesive, SNV single nucleotide variant, TMB tumor mutation burden, TMB-H tumor mutational burden-high, TMB-L tumor mutational burden-low
  2. aTumors with TMB < 10 Muts/Mb are defined as TMB-L, while ≥ 10 Muts/Mb defined as TMB-H
  3. bPearson’s Chi-square test (or Fisher’s exact test) was used in statistical analyses. Values in italic are statistically significant